Potential advantages of ketamine over electroconvulsive therapy in the treatment of nonrefractory severe depression in older patients with multiple medical comorbidities.

Depression in older adults with multiple medical comorbidities can contribute to clinical deterioration, and increased mortality. Electroconvulsive therapy (ECT) is the first-line treatment for these patients. This study aimed to evaluate the effectiveness and safety of subcutaneous (SC) ketamine as an alternative to ECT. We reviewed the medical records of all consecutive older inpatients with severe depression and multiple medical comorbidities who were referred for ECT but treated with SC ketamine over 1 year in our institution. Demographic data, DSM-5 diagnosis, MÅDRS score, and CGI score were analyzed. Twelve patients aged 67-94 years were included. All patients were rated as severely ill, 83% were women, with a mean of 12.6 (SD, 1.4) medical comorbidities. Remission was achieved in 75% of the intention-to-treat population and 100% of treatment completers. The number of sessions ranged from 1 to 6, and days until remission from 1 to 16. Patients remained without relapse for 8-28 months. SC ketamine was safe and well tolerated, and most adverse events were mild and transient. Although limited by the retrospective open-label design of the study and small sample size, our findings provide a potential new indication for ketamine: treatment of severe depression, not necessarily resistant to antidepressants, in older patients with multiple medical comorbidities, at risk of clinical deterioration, and referral for ECT. SC ketamine was highly effective in this population, with no relapse and good tolerance. Randomized controlled trials are needed to adequately test the use of ketamine in this specific group.

Transtorno de acumulação: uma revisão / Hoarding disorder: a review

O transtorno de acumulação (TA) pode ser definido como uma dificuldade persistente de desfazer-se de itens devido ao sofrimento associado com o descarte ou uma necessidade percebida de guardar posses a despeito de seu valor real. Tal comportamento pode resultar no acúmulo de objetos, o que compromete significativamente o uso da moradia, causando sofrimento e/ou prejuízo funcional. Os itens acumulados mais frequentemente são objetos e animais. A prevalência do transtorno é de 1,5 a 2,1% na população em geral, podendo ser maior que 6% em idosos. O TA causa riscos à saúde e à segurança dos indivíduos, especialmente dos idosos, gerando um custo relevante para a sociedade. O diagnóstico de TA é clínico e só deve ser feito após a exclusão de condições médicas gerais e outros transtornos mentais que podem levar ao acúmulo de objetos. O TA parece ser um transtorno de curso crônico e progressivo, comumente associado a comorbidades psiquiátricas. Estudos indicam a participação de fatores genéticos, familiares, cognitivos e de experiências traumáticas na etiologia do TA. A abordagem terapêutica mais estudada até o momento foram as psicoterapias, mas os resultados mostram efeito pequeno. Os estudos farmacológicos existentes são muito incipientes, não permitindo conclusões de eficácia.

Hoarding disorder can be defined as a persistent difficulty in discarding items, due to distress associated with such disposal or a perceived need to save items regardless of their actual value. Such behavior must result in the accumulation of clutter, which significantly compromises living conditions, causing distress and/or functional impairment. The most frequently hoarded items are objects and animals. The point prevalence of clinically significant hoarding was estimated to be 1.5 to 2.1% in the general population, and may exceed 6% in the elderly. HD poses a range of health and safety hazards to individuals, especially older adults, generating significant costs to society. The diagnosis of HD is clinical, and should only be established after general medical conditions and other mental disorders that can lead to accumulating behavior have been ruled out. HD appears to follow a chronic, progressive course, and is commonly associated with psychiatric comorbidities. Studies indicate that genetic, familial, cognitive, and traumatic factors are implicated in the etiology of HD. To date, psychotherapies have been the most widely studied therapeutic approaches, but the results of these studies show small effects. Research into pharmacological approaches to HD is still incipient, precluding any conclusions of efficacy

Tratamento medicamentoso da depressão maior refratária / Drug treatment of refractory major depression

Introdução: Aproximadamente um terço dos pacientes com depressão não atingem remissão. As estratégias medicamentosas mais comumenteutilizadas para a abordagem da depressão resistente são a substituição, a potencialização e a combinação de antidepressivos. Objetivo: Realizar revisão narrativa da literatura em relação a essas estratégias. Metodologia: Buscas sistemáticas no PubMed, Cochrane Library e Lilacs de estudos sobre o tratamento medicamentoso da depressão refratária foram realizadas, considerando artigos publicados até 30 de agosto de 2015. Resultados: Foram selecionados 11 artigos, sendo 6 sobre substituição, 3 acerca de potencialização e 2 sobre combinação de antidepressivos. Conclusão: As estratégias medicamentosas para o tratamento da depressão refratária foram pouco estudadas. O número de ensaios clínicos é pequeno e as limitações metodológicas são significativas. Evidências de eficácia são observadas apenas na potencialização com o lítio, hormônio tireoidiano e alguns antipsicóticos de segunda geração. Ensaios controlados com placebo, com número adequado de pacientes e de curto e longo prazo, estudos para identificação de estratégias mais eficazes em subgrupos e análises de custo-benefício são necessários.

Doença mental e estigma / Mental disease and stigma

Estima-se que 450 milhões de pessoas no mundo sofram de transtornos mentais, com elevado custo para indivíduos e sociedade. Percentual de 14% do fardo de doenças é atribuível aos transtornos neuropsiquiátricos, principalmente em decorrência da natureza crônica e incapacitante da depressão e de outros transtornos psiquiátricos comuns. Pessoas com doenças mentais graves lutam contra dois problemas: os sintomas, que interferem na autonomia, independência e qualidade de vida, e o estigma social. O estigma associado à doença mental é dos mais importantese difíceis obstáculos para a recuperação e reabilitação do indivíduo; afeta negativamente o tratamento; nega oportunidade de trabalho; impede a autonomia e a realização de objetivos de vida. É capaz de prejudicar a qualidade de vida, inclusive da família e da equipe de saúde que lida com as doenças psiquiátricas. A discriminação pode ser tão incapacitante quanto a própria doença. Além disso, viver em ambiente estigmatizante frequentemente acarreta o autoestigma, que junto com o estigma são dois obstáculos fundamentais à integração social e à vida plena em sociedade.O combate ao estigma é primordial para que o portador de doença mentalviva de forma independente e autônoma, tenha oportunidades de trabalho, persiga suas metas e usufrua de oportunidades com dignidade e plena inserção social.

It is estimated that 450 million people worldwide suffer from mental disorders, with a highcost to individuals and society. The percentage of 14% of the disease burden is attributableto neuropsychiatric disorders, mainly due to the chronic and disabling nature of depressionand other common mental disorders. People with severe mental illness fight two problems:the symptoms that interfere with their autonomy, independence, and quality of life, andthe social stigma. The stigma associated with mental illness is the most important anddifficult obstacle in the recovery and rehabilitation of the individual; it negatively affectsthe treatment; denies job opportunities; prevents autonomy and the achievement of lifegoals. It can impair the quality of life, including that of the family and the health team thatdeals with psychiatric disorders. Discrimination can be as debilitating as the disease itself.Moreover, living in a stigmatizing environment often leads to auto-stigma, which alongwith the disease stigma are two main obstacles to social integration and full life in society.Fighting the stigma is critical to the bearer of mental illness to live independently and autonomously,have job opportunities, pursue life goals, and take advantage of opportunitieswith dignity and full social integration.

Evidências sobre a combinação de antidepressivos na depressão maior / Evidence on the combination of antidepressants in major depression

O objetivo desta revisão narrativa é avaliar as evidências científicas do emprego de combinação de antidepressivos no tratamento da depressão maior. Foram avaliadas duas modalidades de combinação: a introdução da combinação desde o início do tratamento e a associação de um segundo antidepressivo em pacientes que não apresentaram resposta satisfatória com o primeiro antidepressivo. Foram pesquisadas as principais bases de dados até outubro de 2012, sem restrição de língua (PubMed, Cochrane Library, Embase, PsycINFO, Lilacs, registros de ensaios clínicos e bancos de teses) e referências secundárias. Foram utilizadas revisões sistemáticas recentes, ensaios clínicos não contemplados pelas revisões e artigos de revisão sobre o tema. Ambas as formas de combinação de antidepressivos foram muito pouco estudadas. De maneira geral, os ensaios incluíram número muito pequeno de sujeitos e apresentaram problemas metodológicos significativos. Os resultados são controversos. As evidências existentes não permitem conclusões sólidas acerca da eficácia e tolerabilidade do emprego de associações de antidepressivos.

Antidepressants for depression in Parkinson's disease: systematic review and meta-analysis.

Depression is common in Parkinson's disease (PD) and is associated with several poor outcomes. However the literature regarding treatment with antidepressants in this population is controversial. The aim of this paper was to systematically review all randomized controlled trials that studied the efficacy of antidepressants for depression in PD (dPD). Studies were retrieved from PubMed (1966-July 2012), Cochrane Library (-July 2012, issue 7), Embase (1980-July 2012), PsycINFO (1980-July 2012), Lilacs (1982-July 2012), secondary references, clinical trials registries and a thesis database. Only double-blind, randomized controlled trials in which an antidepressant was given as the main treatment and compared with placebo and/or another antidepressant were included. Out of the 1438 studies retrieved, only six could be included. Taking into account the five placebo-controlled trials, the overall risk ratio (RR) for response was 1.36 (0.98, 1.87), indicating no statistically significant superiority of antidepressants over placebo. However, in the sensitivity analysis, the RR for response was 1.41 (1.01, 1.96) and 1.48 (1.05, 2.10) after exclusion of one study with questionable results, and when only studies with low risk of bias were considered, respectively. No specific antidepressant class was superior to placebo. In general antidepressant medications were well tolerated. The results suggest antidepressants may be efficacious in the treatment of dPD. However, the results were unstable. In fact, the small number of trials and methodological drawbacks preclude definitive conclusions about their efficacy and tolerability in dPD.

Antidepressant combination for major depression in incomplete responders--a systematic review.

BACKGROUND: Antidepressant combination has been suggested as a strategy to increase treatment efficacy. The objective of this study was to perform a systematic review and meta-analysis of studies that assessed the effect of antidepressant combination for major depression in patients with incomplete response to an initial antidepressant. METHODS: Studies were retrieved from PubMed (1966-February, 2012), Cochrane Library (-February, 2012), Embase (1980-February, 2012), PsycINFO (1980-February, 2012), Lilacs (1982-February, 2012), clinical trials registry, thesis database (www.capes.gov.br), and secondary references. Included studies had an open label phase in which an initial antidepressant was used for the treatment of major depression and a double blind phase for the incomplete responders that compared monotherapy with the first antidepressant versus the association of a second antidepressant to the first one. RESULTS: Out of the 4,884 studies retrieved, only five satisfied the inclusion criteria. The total number of patients included was 483. Only two small trials reported benefits of adding a second antidepressant to the initial antidepressant. Dropouts due to side effects were not reported in three studies. Meta-analysis was not performed due to the small number of studies, the inconsistency in the direction of effect and the possible instability of effect size. Only limited kinds of combination, involving mianserin, mirtazapine and desipramine were studied. Some properties of the first two drugs such as the anxiolytic, sedative, and orexigenic effects, can mimic depression improvement. LIMITATIONS: Publication bias cannot be ruled out. Only one study included a monotherapy arm with the antidepressant used for augmentation of the first antidepressant. CONCLUSIONS: The practice of using a combination of antidepressants for major depression in incomplete responders is not warranted by the literature.

Combination of antidepressants in the treatment of major depressive disorder: a systematic review and meta-analysis.

The objective was to perform a systematic review and meta-analysis of studies that assessed the effect of the combination of antidepressants from the beginning of the treatment of major depressive disorder. Studies were retrieved from PubMed (1966 to August 2010), Cochrane Library (August 2010), Embase (1980 to August 2010), PsycINFO (1980 to August 2010), Lilacs (1982 to August 2010), clinical trials registry, thesis database (www.capes.gov.br), and secondary references. All randomized controlled trials that compared a combination of antidepressants with a single antidepressant from the beginning of the treatment of major depressive disorder in adults were included. Data analysis was performed using the Review Manager 5.0. Of 3492 studies retrieved, five satisfied the inclusion criteria. In one study, only data about dropouts were included. Antidepressant combination was shown to be better than a single antidepressant considering remission (relative risk [RR], 2.71; 95% confidence interval [CI], 1.69-4.35) and response (RR, 1.55; 95% CI, 1.21-1.97). Mirtazapine plus selective serotonin reuptake inhibitor (SSRI) was superior to an isolated SSRI for remission (RR, 1.88; 95% CI, 1.06-3.33). Tricyclic antidepressant plus SSRI was superior to SSRI for remission and response (RR, 8.58; 95% CI, 1.70-43.32 and RR, 1.78; 95% CI, 1.07-2.93, respectively). There was no difference between combined and monotherapy groups in dropouts owing to adverse effects. The results suggest that antidepressant combination is more efficient than a single antidepressant without a significant decrease in tolerability. However, the small number of clinical trials and methodological problems precludes definitive conclusions.

Neuropsychological performance and menstrual cycle: a literature review.

Approximately 80% of all women of reproductive age experience psychological and physical changes associated with the premenstrual phase. Cognitive alterations are among the most common complaints. In this context, studies have assessed cognitive performance across the menstrual cycle in healthy women and also in women with premenstrual syndrome (PMS). The main objective of the present study was to review the literature on cognitive function in different phases of the menstrual cycle in women of reproductive age, both healthy and with PMS, in particular premenstrual dysphoric disorder (PMDD). We searched MEDLINE and LILACS databases. A total of 27 studies were selected. The studies used heterogeneous methodologies. Most studies suggested that healthy women show small fluctuations in cognitive performance across the menstrual cycle, with low performance scores in the luteal phase for visuospatial and motor skills, attention and concentration, verbal memory, visual memory, working memory, and reaction time. Among women with PMS or PMDD, low performance scores for visuospatial and motor skills, attention and concentration, verbal memory, working memory, reaction time and impulsivity were also detected in the luteal phase. Symptoms observed in PMS/PMDD patients showed low intensity, but greater when compared with healthy women. Evidence indicates fluctuations in cognitive performance in the different phases of the menstrual cycle in healthy and PMS women, with worse performance for women with PMS/PMDD in the luteal phase. However, methodological limitations prevent us from drawing solid conclusions. Further studies are needed to investigate the impact of these cognitive fluctuations on patients' daily activities.

Desempenho neuropsicológico e ciclo menstrual: revisão da literatura / Neuropsychological performance and menstrual cycle: a literature review

Approximately 80% of all women of reproductive age experience psychological and physical changes associated with the premenstrual phase. Cognitive alterations are among the most common complaints. In this context, studies have assessed cognitive performance across the menstrual cycle in healthy women and also in women with premenstrual syndrome (PMS). The main objective of the present study was to review the literature on cognitive function in different phases of the menstrual cycle in women of reproductive age, both healthy and with PMS, in particular premenstrual dysphoric disorder (PMDD). We searched MEDLINE and LILACS databases. A total of 27 studies were selected. The studies used heterogeneous methodologies. Most studies suggested that healthy women show small fluctuations in cognitive performance across the menstrual cycle, with low performance scores in the luteal phase for visuospatial and motor skills, attention and concentration, verbal memory, visual memory, working memory, and reaction time. Among women with PMS or PMDD, low performance scores for visuospatial and motor skills, attention and concentration, verbal memory, working memory, reaction time and impulsivity were also detected in the luteal phase. Symptoms observed in PMS/PMDD patients showed low intensity, but greater when compared with healthy women. Evidence indicates fluctuations in cognitive performance in the different phases of the menstrual cycle in healthy and PMS women, with worse performance for women with PMS/PMDD in the luteal phase. However, methodological limitations prevent us from drawing solid conclusions. Further studies are needed to investigate the impact of these cognitive fluctuations on patients' daily activities.

Cerca de 80% das mulheres em idade fértil apresentam alterações psicológicas e físicas associadas à fase pré-menstrual. Dentre as queixas mais comuns estão as alterações cognitivas. Nesse contexto, tem-se estudado o desempenho cognitivo ao longo do ciclo menstrual de mulheres com e sem síndrome pré-menstrual (SPM). O objetivo principal deste estudo foi revisar a literatura acerca do desempenho das funções cognitivas nas diferentes fases do ciclo menstrual de mulheres em idade reprodutiva, sadias ou portadoras de SPM, em particular o transtorno disfórico pré-menstrual (TDPM). Foram revisadas as bases de dados MEDLINE e LILACS. Um total de 27 estudos foram selecionados. Os estudos eram heterogêneos em suas metodologias. Em sua maioria, os trabalhos evidenciaram que mulheres sadias apresentam variações leves no desempenho cognitivo ao longo do ciclo menstrual, obtendo menor pontuação, durante a fase lútea, nas habilidades visuoespaciais e motoras, atenção e concentração, memória verbal, memória visual, memória de trabalho e tempo de reação. Entre as mulheres com SPM ou TDPM, foi identificada, na fase lútea, redução no desempenho das habilidades visuoespaciais e motoras, atenção e concentração, memória verbal, memória de trabalho, tempo de reação e impulsividade. Tais sintomas apresentaram intensidade leve, porém superior à observada em mulheres sadias. As evidências indicam a existência de variações no desempenho cognitivo ao longo das diferentes fases do ciclo menstrual de mulheres sadias ou com SPM, com desempenho cognitivo pior em mulheres com SPM/TDPM na fase lútea. Entretanto, limitações metodológicas impedem conclusões sólidas. Novos estudos são necessários para investigar o impacto dessas oscilações cognitivas nas atividades cotidianas dos pacientes.

Insomnia subtypes and their relationship to excessive daytime sleepiness in Brazilian community-dwelling older adults.

STUDY OBJECTIVES: To investigate the association between different types of insomnia as exposures and excessive daytime sleepiness (EDS) as a binary outcome in older Brazilian residents. DESIGN: The baseline examination of the Bambuí Health and Ageing Study (BHAS), which is an ongoing population-based prospective cohort study of older adults. SETTING: Bambuí (15,000 inhabitants), a city in the State of Minas Gerais, Southeast Brazil PARTICIPANTS: All residents aged ≥ 60 years were eligible to take part in the BHAS baseline. Of 1742 residents identified who were ≥ 60 years, 1606 (92.2%) were interviewed and received comprehensive examinations of health status. INTERVENTIONS: None. MEASUREMENTS AND RESULTS: EDS was defined as the presence of sleepiness ≥ 3 times per week in the last month, causing any interference in usual activities. All insomnia subtypes were significantly associated with EDS in unadjusted analyses, and these associations were only modestly altered after adjusting incrementally for the other covariates. In a final model, the 3 insomnia subtypes were entered into a fully adjusted model simultaneously to investigate mutual independence, giving prevalence ratios of 1.63 (95% CI 1.14-2.31) for initial insomnia, 2.13 (95% CI 1.48-3.07) for middle insomnia, and 1.36 (95% CI 0.94-1.96) for terminal insomnia. The population attributable fractions for initial, middle, and terminal insomnia on prevalence of EDS were 17.6%, 32.9%, and 9.7%, respectively. CONCLUSIONS: Middle insomnia emerged as the insomnia subtype most strongly associated with EDS. Further research is required to clarify causal pathways underlying this cross-sectional association.

Alterações cognitivas na esquizofrenia: atualização / Cognitive impairment in schizophrenia: an update

As alterações cognitivas são características centrais na esquizofrenia. Elas permanecem relativamente estáveis durante todo o curso da doença, não sendo secundárias a outros sintomas ou a efeitos colaterais de psicofármacos. Estão diretamente ligadas a prejuízo funcional e a pior qualidade de vida dos pacientes. Diversos estudos vêm sendo realizados no sentido de caracterizar as principais alterações cognitivas na esquizofrenia, identificar suas bases neurobiológicas e padronizar instrumentos de pesquisa, fundamentais para o advento de novos alvos para intervenções farmacológicas na esquizofrenia. O objetivo deste trabalho foi fazer uma atualização sobre o assunto.

Cognitive dysfunctions are among the core features of schizophrenia. They remain relatively stable throughout the course of the disease, and are secondary neither to other symptoms nor to side effects of psychotropic drugs. Cognitive deficits are directly associated with functional impairment and poor quality of life. Many studies have been conducted to describe the main cognitive abnormalities observed in schizophrenia, to identify their neurobiological bases, and to standardize research instruments, which are of paramount importance for the identification of new targets for pharmacological interventions in schizophrenia. The main objective of this paper was to provide an updated review of the subject.

Versão brasileira da Escala de Avaliação da Cognição em Esquizofrenia (SCoRS-Br): validação em contextos clínicos sem informantes / Brazilian version of the Schizophrenia Cognition Rating Scale (SCoRS-Br): validation in clinical settings without informants

OBJETIVO: A SCoRS é uma medida coprimária de avaliação da cognição na esquizofrenia, baseada em entrevista, relacionada à performance cognitiva e ao funcionamento no mundo real. Em sua versão original, envolve entrevistas com pacientes e informantes. O objetivo do presente trabalho foi buscar evidências de validade de construto convergente e de fidedignidade da versão brasileira da SCoRS (SCoRS-Br) em contextos sem disponibilidade de informantes qualificados. MÉTODO: Foram incluídos 49 pacientes com diagnóstico de esquizofrenia, segundo o DSM-IV. A validação de construto convergente foi realizada utilizando-se o teste R1 e o Miniexame do Estado Mental (MEEM) como instrumentos-padrão. Estimativas de correlação foram avaliadas pelo método de Pearson. Avaliou-se, ainda, a consistência interna da SCoRS. RESULTADOS: A correlação de Pearson entre os resultados da SCoRS sob a perspectiva do entrevistador e os resultados do teste R1 mostrou-se baixa, mas significativa. O coeficiente de Cronbach foi de 0,8829 para a SCoRS examinador e 0,8468 para a SCoRS paciente e o split-half foi de 0,811 e 0,806, respectivamente. CONCLUSÕES: Os resultados evidenciam a validade convergente e fidedignidade da SCoRS, mesmo empregada sem a utilização de informantes. Estudos são necessários para a investigação dos demais critérios de validação.

OBJECTIVE: The SCoRS is an interview-based co-primary measure of cognitive function in schizophrenia that is related to cognitive performance as well as to real-world functioning. Its original version involves interviews with patients and informants. The objective of this study was to seek evidence of convergent validity and reliability of the Brazilian version of SCoRS (SCoRS-Br) with patients in clinical settings without qualified informants. METHOD: Forty nine patients with schizophrenia (DSM-IV) were assessed with the SCoRS-Br two potential convergent validators: the R1 test and the Mini Mental State Evaluation (MMSE). Pearson correlations between the mean scores of the instruments were estimated. Internal consistence of the SCoRS-Br was also evaluated. RESULTS: Pearson correlation between the SCoRS-Br interviewer rating and the R1 test was low but significative. Cronbach's coefficients were 0.8829 for the interviewer rating and 0.8468 for the patient rating. Split-half were 0.811 and 0.806 respectively. CONCLUSIONS: The results showed the convergent validity and reliability of the SCoRS-Br even when used without informants. Other studies are required to investigate other validation criteria.

Duloxetine treatment for women with premenstrual dysphoric disorder: a single-blind trial.

Premenstrual dysphoric disorder (PMDD) affects 3-8% of women of reproductive age and is characterized by severe mood symptoms that cause important functional impairment. Serotonergic antidepressants appear to be an effective treatment for this disorder. The purpose of this study was to collect evidence on the efficacy and tolerability of duloxetine, a dual reuptake inhibitor of serotonin and norepinephrine, in the treatment of PMDD. We conducted a pilot, single-blind, non-controlled, fixed-dose trial. After two cycles for diagnosis confirmation, including a single-blind placebo cycle, 20 women with PMDD were treated continuously for three menstrual cycles with 60 mg/d duloxetine. The primary measure of the efficacy of treatment with duloxetine was the significant reduction in premenstrual symptoms demonstrated by the comparison between the mean Daily Record of Severity of Problems (DRSP) scores at baseline to endpoint (p=0.0002). Statistically significant symptom reduction was observed in the first treatment cycle and throughout all the treatment phase. Clinical response, defined as a reduction 50% of baseline premenstrual symptoms, occurred in 65% of subjects (intention-to-treat population). Significant improvements were demonstrated by secondary measures, including reduction in self-rated functional impairment (p=0.01) and improvement in quality of life (p=0.04). The main side-effects associated with duloxetine were dry mouth, nausea, drowsiness, insomnia, decreased appetite, decreased libido, and sweating. Duloxetine was effective and generally well tolerated in the treatment of PMDD. Further large-scale, double-blind, placebo-controlled studies are needed to evaluate duloxetine as an additional treatment strategy for the management of PMDD.

Erro médico em psiquiatria: caso clínico / Psyquiatry medical error: a clinical case

Os autores relatam caso de suicídio em que os peritos concluíram por falha no atendimento médico prestado (erro médico). Uma senhora foi atendida e internada em hospital psiquiátrico. As anotações médicas no prontuário descreviam paciente com quadro depressivo grave, com ideias de ruína e intenção suicida. A paciente suicidou-se. Foi aberto inquérito policial por imposição da lei brasileira. Os peritos responsáveis pelo laudo concluíram pela possibilidade de falha no atendimento em virtude da ausência de solicitação de acompanhante para a paciente e em função de conduta terapêutica pouco incisiva em relação à gravidade descrita no prontuário.

The authors relate a case of suicide where experts concluded that there had been a medical error. A woman was seen by a physician and admitted to a psychiatric hospital. The doctor's notes described the patient as having a severe depressive episode, with ideas of helplessness and worthlessness and suicidal intention. The patient committed suicide. Brazilian law dictated the opening of a police investigation. The experts responsible for the report concluded that a medical error had possibly been committed: the patient had been left unaccompanied and the therapeutic conduct was not incisive enough in relation to the severity of the episode, as described in the patient's record.